转移性去势敏感性前列腺癌的突变图谱:再审视谱系理论
该回顾性研究对269例原发肿瘤和25个转移灶进行临床级测序,分析转移性去势敏感性前列腺癌(mCSPC)的体细胞突变谱。结果显示TP53、WNT和细胞周期基因的驱动突变频率随转移负荷增加而升高,TP53突变与更短的影像学无进展生存期(rPFS)和至去势抵抗时间相关。结论提示体细胞突变谱可提供寡转移的生物学定义,补充单纯基于病灶数量的定义。
要点
- TP53突变频率随mCSPC转移负荷增加而升高(p=0.01)。
- 寡转移患者中TP53突变与更短rPFS(26.7 vs 48.6月)和至CRPC时间相关。
- TP53和DNA双链断裂修复突变与更多转移灶数量相关。
核心结论
- 体细胞突变谱揭示了转移生物学的谱系,有助于在单纯病灶计数之外重新定义寡转移。
研究设计与样本
- 回顾性研究,纳入269例原发肿瘤和25个转移灶的mCSPC患者,进行临床级测序。
- 患者分类为生化复发(微转移)、异时性寡转移(≤5个病灶)、异时性多转移(>5个病灶)或新发转移。
主要发现
- TP53(p=0.01)、WNT(p=0.08)和细胞周期(p=0.04)基因的驱动突变频率随mCSPC谱系增加。
- 寡转移患者中,TP53突变与更短rPFS(26.7 vs 48.6月;p=0.002)和至CRPC时间(95.6 vs 155.8月;p=0.02)相关。
- 多转移患者中,TP53野生型rPFS为42.7月,TP53突变型为18.5月(p=0.01)。
- TP53突变(IRR 1.45;p=0.004)和DNA双链断裂修复突变(IRR 1.61;p<0.001)与更多转移灶数量相关。
- 多变量分析中,TP53突变独立与更短rPFS(HR 1.59;p=0.03)和CRPC发生(HR 1.71;p=0.01)相关。
临床怎么用
- 肿瘤突变谱可能为寡转移提供生物学定义,补充当前基于病灶数量的定义。
局限性
- 回顾性研究设计。
- 样本量有限。
- 使用商业测序平台,导致预设基因集有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Emerging data suggest that metastasis is a spectrum of disease burden rather than a binary state, and local therapies, such as radiation, might improve outcomes in oligometastasis. However, current definitions of oligometastasis are solely numerical. OBJECTIVE: To characterize the somatic mutational landscape across the disease spectrum of metastatic castration-sensitive prostate cancer (mCSPC) to elucidate a biological definition of oligometastatic CSPC. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective study of men with mCSPC who underwent clinical-grade sequencing of their tumors (269 primary tumor, 25 metastatic sites). Patients were classified as having biochemically recurrent (ie, micrometastatic), metachronous oligometastatic (≤5 lesions), metachronous polymetastatic (>5 lesions), or de novo metastatic (metastasis at diagnosis) disease. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We measured the frequency of driver mutations across metastatic classifications and the genomic associations with radiographic progression-free survival (rPFS) and time to castrate-resistant prostate cancer (CRPC). RESULTS AND LIMITATIONS: The frequency of driver mutations in TP53 (p = 0.01), WNT (p = 0.08), and cell cycle (p = 0.04) genes increased across the mCSPC spectrum. TP53 mutation was associated with shorter rPFS (26.7 vs 48.6 mo; p = 0.002), and time to CRPC (95.6 vs 155.8 mo; p = 0.02) in men with oligometastasis, and identified men with polymetastasis with better rPFS (TP53 wild-type, 42.7 mo; TP53 mutated, 18.5 mo; p = 0.01). Mutations in TP53 (incidence rate ratio [IRR] 1.45; p = 0.004) and DNA double-strand break repair (IRR 1.61; p < 0.001) were associated with a higher number of metastases. Mutations in TP53 were also independently associated with shorter rPFS (hazard ratio [HR] 1.59; p = 0.03) and the development of CRPC (HR 1.71; p = 0.01) on multivariable analysis. This study was limited by its retrospective nature, sample size, and the use of commercially available sequencing platforms, resulting in a limited predefined set of genes examined. CONCLUSIONS: Somatic mutational profiles reveal a spectrum of metastatic biology that helps in redefining oligometastasis beyond a simple binary state of lesion enumeration. PATIENT SUMMARY: Oligometastatic prostate cancer is typically defined as less than three to five metastatic lesions and evidence suggests that using radiation or surgery to treat these sites improves clinical outcomes. As of now, treatment decisions for oligometastasis are solely defined according to the number of lesions. However, this study suggests that tumor mutational profiles can provide a biological definition of oligometastasis and complement currently used numerical definitions.
引用
- Deek MP, Van der Eecken K, Phillips R, et al. The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. Eur Urol. 2021. PMID: 33419682. doi:10.1016/j.eururo.2020.12.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。